PROGRAMME

Friday, September 6, 2019

Introductory Lectures

Chair: Franco Bazzoli, Herbert Tilg

08.30 – 09.30 hrs

08.30 - 09.00

What’s hot in Helicobacter pylori?

Kentaro Sugano, Japan

9.00 - 09.30         

What’s hot in Microbiota?

Eran Elinav, Rehovot, Israel

Symposium: Microbiota and GI/liver cancer

Chair: Lars Engstrand, Herbert Tilg

09.30 – 11.10 hrs

09.30 - 09.50

Gastro-duodenal dysbiosis in functional dyspepsia: the missing link?
Carmelo Scarpignato, Italy

09.50 - 10.10 

Microbiota and its role in oesophageal and gastric cancer

Ceu Figueiredo, Porto, Portugal

10.10 - 10.30     

H. pylori infections and associated (pre)malignant lesions of the stomach

Michiel Mommersteeg, Amsterdam, The Netherlands

10.30 - 10.50

Liver cancer

Francesca Romana Ponziani, Rome, Italy

10.50 - 11.10

Cancer therapies and microbiota

Georgina Hold, Sydney, Australia

Coffee Break

11.10 - 11.30 hrs

 

Symposium:  Gastric Carcinogenesis

Chair: Yong Chan Lee, Ari Ristimäki

11.30 – 13.10 hrs

11.30 - 11.50

Do animal models provide answers in gastric carcinogenesis?

James Fox, Boston, MA, US

 

11.50 - 12.10

Immunopathogenesis in gastric cancer

Mario Milco D’Elios, Florence, Italy

 

​The role of intestinal metaplasia in gastric carcinogenesis: 


12.10 - 12.30

  • The endoscopic & clinical approach
    Mario Dinis-Ribeiro, Porto, Portugal

 

12.30 - 12.50

  • The histopathological approach
    Massimo Rugge, Padova, Italy

 

12.50 – 13.10

  • The molecular approach
    Ki-Taek Nam, Seoul, Korea

​​​Lunch Break & Poster Viewing

13.10 – 14.00 hrs

 

Impact of H. pylori eradication on gastric cancer risk

Chair: Jae Gyu Kim, Marcis Leja

14.00 – 14.30 hrs

  • In the East
    Il Ju Choi, Seoul, Korea

  • In the West
    Theodore Rokkas, Athens, Greece

Parallel Workshops from Submitted Abstracts 1

Diagnosis and Epidemiology

Chair: Theodore Rokkas, Christoph Steininger

14.30 – 16.00 hrs

W1.1

Apparent intracellular Helicobacter pylori detected by immunohistochemistry - the missing link in eradication failure

A. Beer1, H. Hudler2, M. Kundi1, S. Hudler2, M. Hader3, V. Taeuber1, H. Schachner1, S. Gruber2, A. M. Hirschl1, R. Kain1, A. Makristathis1

1Medical University Vienna, Vienna, Austria, 2Histopathologic practice Winzendorf, Winzendorf, Austria, 3Wilhelminenspital, Vienna, Austria.

 

W1.2

Impact of implementing a real-time PCR assay on the workflow and laboratory diagnosis of Helicobacter pylori infection from gastric biopsies

T. Huang, P. Bogaerts, M. Hoebeke, W. Bouchahrouf, C. Berhin, Y. Glupczynski

National Reference Center for Helicobacter pylori, Yvoir, Belgium.

 

W1.3

Impaired sensitivity of invasive tests for Helicobacter pylori infection in patients with severe chronic atrophic gastritis

L. Koletzko1, K. Schütte2, L. Macke1, R. Vasapolli1, A. Link3, P. Malfertheiner1, C. Schulz1

1Department of Medicine II, University Hospital, LMU Munich, München, Germany, 2Department of Internal Medicine and Gastroenterology, Niels-Stensen-Kliniken, Osnabrück, Germany, 3Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, Madgeburg, Germany.

 

W1.4

Performance of multiplex serology in discriminating active versus past Helicobacter pylori infection

J. Butt1,2, W. J. Blot3, M. J. Shrubsole4, M. G. Varga5, L. Hendrix6, S. Crankshaw1, T. Waterboer2, M. Pawlita2, M. Epplein1;
1Cancer Control and Population Health Sciences Program, Duke Cancer Institute and Department of Population Health Sciences, Duke University, Durham, NC, United States, 2Infection and Cancer Epidemiology, Division of Molecular Diagnostics of Oncogenic Infections, German Cancer Research Center, Heidelberg, Germany, 3Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN, United States, 4Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States, 5Department of Epidemiology, University of North Carolina Gillings School for Global Public Health and the Lineberger Comprehensive Cancer Center, Chapel Hill, NC, United States, 6Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, United States.

 

W1.5

Racial differences in Helicobacter pylori antibody prevalence by year of birth and demographic factors in a consortium of US adults

M. G. Varga1, J. Butt2, W. J. Blot3, L. Le Marchand4, C. Haiman5, Y. Chen6, S. Wassertheil-Smoller7, G. Y. F. Ho8, L. E. Tinker9, R. M. Peek3, J. D. Potter9, T. L. Cover3, L. Hendrix2, T. Hyslop2, A. Zeleniuch-Jacquotte6, S. Berndt10, A. Hildesheim10, T. Waterboer11, M. Pawlita11, M. Epplein2

1University of North Carolina, Chapel Hill, NC, United States, 2Duke Cancer Institute, Durham, NC, United States, 3Vanderbilt University Medical Center, Nashville, TN, United States, 4University of Hawaii Cancer Center, Honolulu, HI, United States, 5University of Southern California, Los Angeles, CA, United States, 6New York University, New York, NY, United States, 7Albert Einstein College of Medicine, Bronx, NY, United States, 8Northwell Health, Great Neck, NY, United States, 9Fred Hutchinson Cancer Research Center, Seattle, WA, United States, 10National Cancer Institute, Rockville, MD, United States, 11German Cancer Research Center, Heidelberg, Germany.

 

W1.6

Seroprevalence and determinants of Helicobacter pylori infection in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)

S. H. Tsang1, M. Avilés-Santa2, C. C. Abnet1, M. O. Brito3, R. D. Burk4, M. L. Daviglus3, S. Wassertheil-Smoller4, S. Castaneda5, B. I. Graubard1, B. Thyagarajan6, M. Camargo1

1National Cancer Institute, Rockville, MD, United States, 2National Institute on Minority Health and Health Disparities, Rockville, MD, United States, 3University of Illinois, Chicago, IL, United States, 4Albert Einstein College of Medicine, Bronx, NY, United States, 5San Diego State University, Calexico, CA, United States, 6University of Minnesota, Minneapolis, MN, United States.

 

W1.7

Decreased pepsinogen level in relation to presence of menopause in the GISTAR study population in Latvia

J. Aleksejeva1, D. Razuka-Ebela1,2, I. Daugule1,2, I. Polaka2, S. Parshutin2, D. Santare1,2, I. Ebela1, R. Murillo3, R. Herrero3, J. Park3, M. Leja1,2

1Faculty of Medicine, University of Latvia, Riga, Latvia, 2Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia, 3International Agency for Research on Cancer, Lyon, France.

 

Parallel Workshops from Submitted Abstracts 2

H. pylori pathogenesis

Chair: Annemieke Smet, Christine Josenhans

14.30 – 16.00 hrs

 

W2.1

R-Spondin 3 links gastric epithelial stem cell regeneration to antimicrobial defense against Helicobacter pylori

M. Sigal1,2, T. Meyer1

1Max-Planck-Insitute for Infection Biology, Berlin, Germany, 2Charite University Medicine Berlin, Department of Gastroenterology, Berlin, Germany.

 

W2.2

Helicobacter pylori CagA induces intestinal metaplasia in normal human gastric epithelial cells

T. Meyer, M. Reines

Department of Molecular Biology; Max Planck Institute for Infection Biology, Berlin, Germany.

 

W2.3

Inhibition of Autophagy aggravates DNA damage response via Rad51 ubiquitination in response to H. pylori infection.

C. Xie, N. Li, H. Wang, C. He, Y. Hu, C. Peng, J. Chen, X. Shu, Y. Zhu, N. Lu

Department of Gastroenterology, Nanchang, China.

 

W2.4

The innate immune molecule NLRC5 protects against Helicobacter-induced gastric B cell lymphomagenesis

M. Chonwerawong1, J. Ferrand1, H. Chaudhry1, C. Higgins1, L. Tran1, M. Walker2, P. S. Bathal3, A. Dev4, G. Moore4, W. Sievert4, B. J. Jenkins1, M. D'Elios5, D. J. Philpott6, T. A. Kufer7, R. L. Ferrero1

1Hudson Institute of Medical Research, Monash University, Melbourne, Australia, 2The University of Newcastle, Newcastle, Australia, 3University of Melbourne, Melbourne, Australia, 4Monash Health, Monash University, Melbourne, Australia, 5University of Florence, Florence, Italy, 6University of Toronto, Toronto, ON, Canada, 7University of Hohenheim, Stuttgart, Germany.

 

W2.5

DNA hypermethylation downregulates Telomerase Reverse Transcriptase (TERT) during H. pylori-induced chronic inflammation.

F. I. Bussière1, V. Michel2, J. Fernandes2, L. Costa2,3, V. Camilo2, H. De Reuse2, L. Fiette2,4, E. TOUATI2

1INRA, Nouzilly, France, 2Institut Pasteur, Paris, France, 3Institut Cochin, Paris, France, 4Institut Mutualiste Montsouris, Paris, France.

 

W2.6

Helicobacter pylori dampens MHC-II expression on macrophages via the up-regulation of miRNAs targeting CIITA

M. de Bernard, G. Codolo, M. Toffoletto, F. Chemello, S. Coletta, G. Soler Teixidor, G. Battaggia, G. Munari, M. Fassan, S. Cagnin

University of Padova, Padova, Italy.

 

W2.7

H. pylori epigenome micro-evolution associated with DNA methyltransferases’ sequence-specificity changes

M. Fukuyo1,2, H. Yano3,4, H. Yonezawa5, N. Takahashi5, K. Yahara6, M. Konno7, T. F. Shibata8, S. Shigenobu8, B. Rahmutulla1, I. Uchiyama8, Y. Hasegawa2, O. Ohara2, A. Kaneda1, I. Kobayashi3,5,9

1Chiba University, Chiba, Japan, 2Kazusa DNA Research Institute, Kisarazu, Japan, 3The University of Tokyo, Tokyo, Japan, 4Tohoku University, Sendai, Japan, 5Kyorin University, Tokyo, Japan, 6National Institute of Infectious Diseases, Tokyo, Japan, 7Sapporo Kosei General Hospital, Sapporo, Japan, 8National Institute for Basic Biology, Okazaki, Japan, 9University Paris-Saclay, Paris, France.

Coffee Break

16.00 - 16.30 hrs

 

State of the Art Lectures

Chair: Luiz Coelho, Giovanni Gasbarrini

16.30 – 17.30 hrs

“Test and Treat” strategy with urea breath test: a cost-effective strategy for the management of Hp infection in Spain

Ariel Beresniak, Geneva, Switzerland

 

The Gut-Brain Axis

Annemieke Smet, Antwerp, Belgium

 

Parallel Workshops from Submitted Abstracts 3

Treatment of Helicobacter Infection I

Chair: Francesco di Mario, Jong Jae Park

17.30 – 19.15 hrs

W3.1

Is Helicobacter pylori cure a life-long strategy? A 25 years survey on 693 patients

F. Di Mario1, A. Barchi1, M. Russo1, M. Franceschi2, N. Dal Bò3, R. Cannizzaro4, C. Miraglia1, A. Tursi5, G. Brandimarte6, P. Crafa1, L. Franzoni1, M. Rugge7

1University of Parma-Department of Medicine and Surgery, Parma, Italy, 2Azienda ULSS 7 Pedemontana, Endoscopy Unit-Ospedale Alto Vicentino, Santorso (VI), Italy, 3Gastroenterology and Gastrointestinal Endoscopy Unit, Treviso Hospital, Treviso, Italy, 4Oncological Gastroenterology, CRO Aviano National Cancer Institute, Aviano, Italy, 5Gastroenterology Service, ASL BAT, Andria, Italy, 6Division of Internal Medicine and Gastroenterology, "Cristo Re" Hospital, Rome, Italy, 7Department of Pathology, University of Padova, Padova, Italy.

 

W3.2

High efficacy of 14-day high-dose PPI bismuth-containing quadruple therapy with probiotics supplement for Helicobacter pylori eradication in high clarithromycin resistance areas:A double blinded-randomized placebo-controlled study.

P. Poonyam1,2, R. Vilaichone2,3,4, P. Chotivitayatarakorn2,3,4, V. Mahachai3

1Gastroenterology unit, Faculty of medicine, Srinakharinwirot University, Nakorn Nayok, Thailand, 2Gastroenterology Unit, Thammasat University Hospital, Pathumthani, Thailand, 3National Digestive Diseases Research Center of Thailand, Pathumthani, Thailand, 4Department of Medicine, Chulabhorn International College of Medicine (CICM) at Thammasat University, Pathumthani, Thailand.

 

W3.3

The comparison of effectiveness of standard triple therapy and high-dose amoxicillin/ bismuth therapy in eradication of H. pylori

O. Sjomina1,2, A. Lielause1, A. Rūdule2, E. Martinsone2, D. Pūpola2,3, R. Vangravs2, A. Kiršners2, S. Paršutins2, H. Gorskis2, I. Poļaka2, A. Jeniceka1, E. Cine1, G. Šķenders2, D. Razuka-Ebela1, M. Leja1,2,4

1Faculty of Medicine, University of Latvia, Riga, Latvia, 2Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia, 3Latvian Biomedical Research and Study centre, Riga, Latvia, 4Digestive Diseases Centre GASTRO, Riga, Latvia.

 

W3.4

A multi-center real-life study on comparison between bismuth quadruple (BQ) (10 days) and clarithromycin (CLA) containing non-bismuth quadruple (CT) therapy (10 and 14 days) in the eradication of H. pylori infection in patients naïve to treatment in a region with high CLA and dual resistance

A. G. Gravina1, R. M. Zagari2, G. Nardone3, A. Federico1, M. Dallio1, M. Martorano4, C. Mucherino5, A. Romiti2, L. Avallone1, L. Granata1, L. Colacino1, A. Facchiano1, D. Picascia1, D. Sgambato1, A. Miranda1, L. Romano6, C. Loguercio1, M. Romano1

1Division of Hepatogastroenterology, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, 2Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, 3Division of Gastroenterology, "Federico II" University, Naples, Italy, 4Gastroenterology and Endoscopy Unit, Immacolata Hospital, Sapri, Italy, 5Gastroenterology and Endoscopy Unit, S. Anna-S. Sebastiano Hospital, Caserta, Italy, 6Surgical Digestive Endoscopy, Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.

 

W3.5

Antibiotic-free Lipid Nanoparticles for Gastric Infection Management

C. L. Seabra1,2,3, P. Parreira1,2, P. Henriques1,2, C. Monteiro1,2, J. Gomes1,4, I. Amorim1,4,5, F. Gartner1,4,5, C. Machado1,2, C. Nunes6, S. Reis6, E. Touati7, C. A. Reis1,4,8, I. C. Gonçalves1,2, M. L. Martins1,2,5

1i3S- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal, 2INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal, 3CBQF- Centro de Biotecnologia e Química Fina, Universidade Católica Portuguesa (atual affiliation), Porto, Portugal, 4IPATIMUP – Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal, 5ICBAS- Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal, 6REQUIMTE, Laboratório de Química Aplicada, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal, 7Institut Pasteur, 25-28 Rue du Dr. Roux, 75015, Paris, France, 8Faculdade de Medicina, Universidade do Porto, Porto, Portugal.

 

W3.6

Fate of meta-analyses: the case of Helicobacter pylori

G. M. Buzás; Ferencváros Health Service Non-Profit Ltd, Budapest, Hungary.

 

W3.7

Pan-European Registry on H. pylori management (Hp-EuReg): Analysis of 4,388 second-line treatments

O. P. Nyssen1, A. G. McNicholl1, D. Vaira2, A. Perez-Aisa3, B. Tepes4, D. S. Bordin5, F. Lerang6, T. Rokkas7, M. Leja8, A. Axon9, L. Kupcinskas10, L. Jonaitis10, J. Machado11, O. Shvets12, L. Veijola13, G. Buzás14, H. Simsek15, L. Boyanova16, V. Lamy17, Y. Niv18, M. Venerito19, P. Bytzer20, L. G. Capelle21, A. Goldis22, K. Przytulski23, C. Beglinger24, M. Katicic25, T. Milosavljevic26, G. Fiorini2, M. G. Donday1, F. Megraud27, C. O'Morain28, J. P. Gisbert1

1H. La Princesa, IIS-IP and CIBERehd, Madrid, Spain, 2S. Orsola Malpighi Hospital, Bologna, Italy, 3Agencia Sanitaria Costa del Sol, Marbella, Spain, 4AM DC Rogaska, Rogaska Slatina, Slovenia, 5Moscow Clinical Scientific Center, Moscow, Russian Federation, 6Central Hospital Ostfold, Fredrikstad, Norway, 7Henry Dunant Hospital, Athens, Greece, 8Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia, 9University of Leeds, Leeds, United Kingdom, 10Lithuanian University of Health Sciences, Kaunas, Lithuania, 11Instituto de Investigação e Inovação em Saúde, Universidade do Porto, and Ipatimup - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal, 12nternal Diseases Department No.1, National Medical University named after O.O. Bogomolets, Kyiv, Ukraine, 13Internal Medicine, Herttoniemi Hospital, Helsinki, Finland, 14Ferencváros Policlinic, Budapest, Hungary, 15Hacettepe University Faculty of Medicine, Ankara, Turkey, 16Medical University of Sofia, Sofia, Bulgaria, 17CHU Charleroi, Charleroi, Belgium, 18Rabin Medical Center, Tel Aviv University, Petach Tikva, Israel, 19Otto-von-Guericke University Hospital, Magdeburg, Germany, 20Zealand University Hospital, Copenhagen University, Copenhagen, Denmark, 21Erasmus MC University, Rotterdam, Netherlands, 22Timisoara Hospital, Timisoara, Romania, 23Medical Centre for Postgraduate Education, Warsawa, Poland, 24Medical Centre for Postgraduate Education, Warszawa, Poland, 25University Hospital Merkur Polyclinic Nola, Zagreb, Croatia, 26Clinical Center of Serbia Clinic for Gastroenterology and hepatology, University of Belgrade, Belgrade, Serbia, 27Hôpital Pellegrin, Bordeaux, France, 28Trinity College Dublin, Dublin, Ireland.

 

W3.8

Current treatment of Helicobacter pylori infected children and adolescents in Europe: Interim Results of the new EuroPedHp Registry

T. Le Thi1, K. Werkstetter1, J. Cabral2, K. Kotilea3, P. Bontems3, M. Cilleruelo Pascual4, J. Barrio5, M. Homan6, M. Kori7, P. Urruzuno8, N. Kalach9, Z. Misak10, R. Lima11, M. Tavares11, E. Miele12, A. Chiaro13, V. Urbonas14, K. Matusiewics15, A. Krahl16, M. Korkut Ugras17, A. Papadopoulou18, F. Rea19, J. Sykora20, J. de Laffolie21, M. Klemenak22, M. Rogalidou23, E. Roma24, A. Lopes25, T. Casswall26, A. Cseh27, H. Banoub28, S. Koletzko1, and the Helicobacter pylori Working Group of ESPGHAN

1Dr. von Hauner Children's Hospital, Medical center of the University of Munich, Munich, Germany, 2Hospital of Dona Estefania, CHLC, Lisbon, Portugal, 3Queen Fabiola Children's University Hospital, Brussels, Belgium, 4Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 5Hospital Universitario de Fuenlabrada Madrid, Madrid, Spain, 6University Children's Hospital Ljubljana, Ljubljana, Slovenia, 7Kaplan Medical Center Israel, Rehovot, Israel, 8Hospital Universitario Doce de Octubre, Madrid, Spain, 9Catholic University of Lille, Lille, France, 10Children's Hospital Zagreb, Zagreb, Croatia, 11Centro Hospitalar Universitário do Porto, Porto, Portugal, 12University of Naples 'Federico II', Naples, Italy, 13G.Gaslini Hospital in Genoa, Genoa, Italy, 14Vilnius University Children's Hospital, Vilnius, Lithuania, 15Wroclaw Medical University, Wroclaw, Poland, 16Children's Hospital Prinzessin Margaret, Darmstadt, Germany, 17Yeditepe University Hospital, Istanbul, Turkey, 18University of Athens Children's Hospital 'Agia Sofia', Athens, Greece, 19Bambino Gesù Children's Hospital, Rome, Italy, 20Charles University in Prague, Prague, Czech Republic, 21University Children's Hospital Giessen, Giessen, Germany, 22University Clinical Center Maribor, Maribor, Slovenia, 23University Hospital of Ioannina, Ioannina, Greece, 24Other Medical Centers in Athens, Athens, Greece, 25Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, 26Karolinska University Hospital, Stockholm, Sweden, 27Semmelweis University, Budapest, Hungary, 28Epsom and St. Helier University Hospitals NHS Trust, Carshalton, United Kingdom.

 

Parallel Workshops from Submitted Abstracts 4

Gastric Carcinogenesis

Chair: José Machado, Yaron Niv

17.30 – 19.15 hrs

W4.1

Understanding the tumour-promoting functions of autophagy in gastric carcinogenesis

N. Castano Rodriguez1, A. B. Goswami1, I. Simovic1, H. M. Mitchell1, N. O. Kaakoush1, K. M. Fock2, K. L. Goh3, G. L. Porras-Hurtado4, J. L. Cardona-Deazza4, J. J. Montoya-Martinez4, A. J. Cadavid-Velez4, H. W. Toro-Hidalgo4, A. R. Cobo-Alvarado4, O. D. S. Hincapié-Rincón4

1The University of New South Wales, Sydney, Australia, 2Changi General Hospital, Singapore, Singapore, 3University of Malaya, Kuala Lumpur, Malaysia, 4Clinica Comfamiliar Risaralda, Pereira, Colombia.

 

W4.2

Molecular characterization of the gastric commensal bacteria progressing gastric carcinogenesis in H. pylori-infected gastric mucosa

H. Tsugawa1, J. Matsuzaki1, H. Mori2, M. Suematsu1, H. Suzuki3

1Keio University, Tokyo, Japan, 2National Hospital Organization Tokyo Medical Center, Tokyo, Japan, 3Tokai University, Kanagawa, Japan.

 

W4.3

"Helicobacter pylori-activated gastric fibroblasts induce permanent reprogramming of gastric epithelial cells towards invasive phenotype in vitro"

G. Krzysiek-Maczka1, A. Targosz1, M. Strzalka1, U. Szczyrk1, A. Ptak-Belowska1, J. Czyz2, T. Brzozowski1

1Department of Physiology, Jagiellonian University Medical College, Cracow, Poland, 22Department of Cell Biology, the Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Cracow, Poland.

 

W4.4

Identification of novel serological biomarkers for gastric cancer in the MCC-Spain case-control study based on Helicobacter pylori whole-proteome microarrays

R. Jeske1, D. Reininger1, J. A. Butt1,2, C. Harmel1, B. Turgu1, N. Fernández de Larrea-Baz3,4, V. Martín4,5, V. Moreno4,6, M. Kogevinas4,7, M. Pollán3,4, T. Waterboer1, N. Aragonés4,8, K. Hufnagel1

1German Cancer Research Center (DKFZ), Heidelberg, Germany, 2Duke Cancer Institute and Duke University, Durham, NC, United States, 3National Center of Epidemiology, Carlos III Health Institute (ISCIII), Madrid, Spain, 4CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain, 5University of León, León, Spain, 6Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain, 7Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, 8Department of Health, Madrid, Spain.

 

W4.5

Risk of progression of intestinal metaplasia in a low gastric cancer incidence country.

A. Bowden, J. Weininger, E. Farrell, S. Crowther, D. McNamara, C. O'Morain, A. O'Connor

Tallaght University Hospital/Trinity College Dublin, Dublin, Ireland.

 

W4.6

Prevention of helicobacter pylori-associated gastric carcinogenesis with dietary walnut

K. Hahm1, Y. Shin2

1CHA University, Seongnam, Republic of Korea, 2Inha University, Incheon, Republic of Korea.

 

W4.7

Role of Leukaemia Inhibitory Factor (LIF) on the tumorigenic properties of Cancer Stem Cells in gastric adenocarcinoma

L. Seeneevassen1, J. Giraud1, S. Molina-Castro2, C. Tiffon1, C. Staedel3, O. Martin1, F. Mégraud1,4, P. Lehours1,4, H. Boeuf5, P. Dubus1,4, C. Varon1

1INSERM U1053 BaRITOn, University of Bordeaux, Bordeaux, France, 2INISA-School of Medicine, University of Costa Rica, San José, Costa Rica, 3INSERM U1212 Régulations Naturelles et Artificielles des ARNs, University of Bordeaux, Bordeaux, France, 4CHU de Bordeaux, Bordeaux, France, 5INSERM U1026, Bordeaux, France.

 

W4.8

IL-27 is abrogated in the gastric mucosa and serum of patients with gastric cancer in opposite to duodenal ulcer

D. M. M. Queiroz1, F. F. Melo2, M. M. D. A. Cabral1, B. B. Brito2, F. A. F. Silva2, G. A. Rocha1

1Universidade Federal de Minas Gerais/Faculade de Medicina, Belo Horizonte, Brazil, 2Universidade Federal da Bahia, Vitória da Conquista, Brazil.

Networking Dinner at Stiftskeller

20.00 hrs

Saturday, September 7, 2019

Symposium: Modulation of microbiota

Chair: Georgina Hold, Patrizia Kump

08.00 – 09.40 hrs

08.00 - 08.20

Diet: a major confounder of the gut microbiota

Alexander Moschen, Innsbruck, Austria

                                     

08.20 - 08.40

Probiotics – how and when do they work?

Mirjana Rajilic-Stojanovic, Belgrade, Serbia

 

08.40 - 09.00

Pre-/pro-/antibiotics: how to best manipulate the microbiota?

Laure Bindels, Louvain, Belgium

 

09.00 – 09.20

​FMT: indications and potential

Gianluca Ianiro, Rome, Italy

 

09.20 - 09.40

New Stool Biobanking Initiative

Josbert Keller, Den Haag, The Netherlands

 

Coffee Break

09.40 - 10.30 hrs

Symposium: Helicobacter and other Microbiota in Extragastric Diseases

Chair: Antonio Gasbarrini, Alexander Moschen

10.30 – 12.00 hrs

10.30 - 10.50

Autoimmune & Allergic Disorders

Maria Pina Doré, Sassari, Italy

 

10.50 - 11.10

Metabolic Syndrome & Asthma

Nayoung Kim, Seoul, Korea

 

11.10 - 11.30

Atherothrombosis

Christoph Reinhardt, Mainz, Germany

 

11.30 - 11.50

Neurodegenerative diseases

Claire Roubaud, Bordeaux, France

 

Industry-Sponsored Satellite Symposium

Chair: David Graham

Please click HERE to view details of the session

12.00 – 13.00 hrs

​​​Lunch Break & Poster Viewing

13.00 – 14.00 hrs

Parallel Workshops from Submitted Abstracts 5

Treatment of Helicobacter Infection II

Chair: Javier Gisbert, Athanasios Makristhatis

14.00 – 15.30 hrs

W5.1

Helicobacter pylori Acid Acclimation: The Evil Duo of a pH-Gated Urea Channel and a Cytoplasmic Urease

H. L. Luecke, E. Cunha

University of Oslo, Oslo, Norway.

 

W5.2

Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori

T. Furuta, M. Yamade, T. Kagami, T. Suzuki, T. Higuchi, T. Uotani, S. Tani, M. Iwaizumi, Y. Hamaya, S. Osawa, K. Sugimoto

Hamamatsu University School of Medicine, Hamamatsu, Japan.

 

W5.3

Ten-day concomitant, 10-day sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection: a randomized nationwide trial in Korea

B. Kim1, H. Lee2, J. Kim1, J. Kim2, Korean College of Helicobacter and Upper Gastrointestinal Research

1Chung-Ang University Hospital, Seoul, Republic of Korea, 2SungKyunKwan University College of Medicine, Seoul, Republic of Korea.

W5.4

Effect of Previous Nitroimidazole Treatment on Helicobacter pylori Eradication Success

D. Boltin1, Z. Levi1, R. Gingold-Belfer1, T. Shochat1, I. Dotan1, S. Birkenfeld2, Y. Niv3

1Rabin Medical Center, Petah Tikva, Israel, 2Clalit Health Services, Tel Aviv, Israel, 3Ministry of Health, Jerusalem, Israel.

W5.5

Growing H. pylori resistance to standard antibiotictherapies identified from a phase 3 clinical trial of treatment naive patients in the United States

D. Y. Graham1, K. G. Hulten1, L. B. Lamberth1, R. M. Panas2, I. N. Kalfus3

1Baylor College of Medicine, Houston, TX, United States, 2RedHill Biopharma, Inc., Raleigh, NC, United States, 3RedHill Biopharma, Ltd., Tel Aviv, Israel.

W5.6

European survey of Helicobacter pylori primary resistance to antibiotics - Evolution over the last 20 years

F. Mégraud1, D. Huang2, M. Hoebeke2, C. Alix1, L. Bénéjat1, P. Lehours1, Y. Glupczynski2, The H. pylori AST Working Group

1National Reference Centre for Helicobacters, Bacteriology Laboratory, Pellegrin Hospital, Bordeaux, France, 2National Reference Centre for Helicobacters, Bacteriology Laboratory, CHU UCL Namur (Site Godinne), Yvoir, Belgium.

W5.7

The activity of liposomal linolenic acid against Helicobacter pylori in vitro and its impact on human fecal microbiota

Y. Wang1,2; S. Wu1; Y. An1,2; Y. Wang1; Y. He1; Y. Fu3; Y. Xie1
1Department of Gastroenterology, Nanchang, China; 2School of Pharmacy,
Nanchang University, Nanchang, China; 3School of Pharmacy, Nanchang
University, Nanchang, Nanchang, China

Parallel Workshops from Submitted Abstracts 6

Microbiota in Health and Disease

Chair: Josbert Keller, Mirjana Rajilić-Stojanović

14.00 – 15.30 hrs

W6.1

Functional Microbiomics - Standardized Assessment of Nutrition-Microbiome-Host Interplay by Targeted Metabolomics

H. Pham Tuan, U. Sommer, D. Kirchberg, X. Iwanowa, R. Talmazan, M. Buratti, B. Wolf, T. Koal, W. Fischer-Knuppertz

BIOCRATES Life Sciences, Innsbruck, Austria.

 

W6.2

Combining nucleic acid mimics and spectral imaging with fluorescence in situ hybridization for the analysis of the gastric micro-biogeography

A. S. Azevedo1,2,3, H. Teixeira1, R. Ferreira2,3, C. Figueiredo2,3, J. Wengel4, C. Almeida1,5,6, N. Azevedo1

1LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465, Porto, Portugal, 2i3S Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal, 3IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal, 4Nucleic Acid Center, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, Denmark, 5National Institute for Agrarian and Veterinary Research (INIAV), Rua dos Lagidos, Lugar da Madalena, 4485-655 Vairão, Vila do Conde, Portugal, 6Centre of Biological Engineering, Universidade do Minho, Campus de Gualtar, 4710-057, Braga, Portugal.

 

W6.3

Patients with small intestinal bacterial overgrowth (SIBO) have distinct microbiome characteristics including post Helicobacter pylori eradication treatment

T. T. Perets1,2, O. Ashorov1, D. Hamouda1, S. Ben Simon3, D. Boltin4,2, O. Koren3, R. Dickman4,2

1Rabin Medical Center - Gastroenterology Laboratory, Petah Tikva, Israel, 2Tel Aviv University - Sackler Faculty of Medicine, Tel Aviv, Israel, 3Bar Ilan University - Azrieli Faculty of Medicine, Zefat, Israel, 4Rabin Medical Center - Division of Gastroenterology, Petah Tikva, Israel.

 

W6.4

The difference of gut microbiome in the stage of colorectal cancer and change of gut microbiome after surgery or chemotherapy

J. Cho1, D. Lee1,2, Y. Lee2, M. Seol2, Y. Kim3, W. Lee4, Y. Kim4, Y. Park1, C. Shin1, H. Yoon1, N. Kim1, S. Seol5

1Seoul National University Bundang Hospital, Seongnam, Republic of Korea, 2R&D center, BioBankHealing Inc,, Seongnam, Republic of Korea, 3Graduate School of Medical Science & Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, 4MD Healthcare Inc., Seoul, Republic of Korea, 5Inje University Busan Paik Hospital, Busan, Republic of Korea.

 

W6.5

Microbiota changes induced by Microencapsulated Sodium Butyrate

S. Facchin1, N. Vitulo2, M. Calgaro2, A. Buda3, R. Chiara4, B. Perini1, G. Lorenzon1, C. Marinelli1, E. Savarino1

1University of Padua, DiSCOG,Padua, Italy, Padua, Italy, 2University of Verona, Department of Biotechnology, Verona, Italy, 3UOC Gastroenterology, Feltre, Belluno, Italy, 4University of Padua, Department of Biology,, Padua, Italy.

W6.6

Saccharomyces boulardiiCNCM I-745as complementary treatment of Helicobacter pylori infection on gut microbiome

P. Cardenas1, M. Baldeon2, H. Cohen3, M. Fornasini4, D. Garces5, B. Prado5, N. Flores4, I. Salvador4, O. Cargua4

1Instituto de Microbiologia - Universidad San Francisco de Quito, Quito, Ecuador, 2CENBIO - Universidad UTE, Quito, Ecuador, 3Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, 4CENBIO, Quito, Ecuador, 5Instituto de Microbiologia, Quito, Ecuador.

 

W6.6

Saccharomyces boulardiiCNCM I-745as complementary treatment of Helicobacter pylori infection on gut microbiome

P. Cardenas1, M. Baldeon2, H. Cohen3, M. Fornasini4, D. Garces5, B. Prado5, N. Flores4, I. Salvador4, O. Cargua4

1Instituto de Microbiologia - Universidad San Francisco de Quito, Quito, Ecuador, 2CENBIO - Universidad UTE, Quito, Ecuador, 3Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, 4CENBIO, Quito, Ecuador, 5Instituto de Microbiologia, Quito, Ecuador.

W6.7

Efficacy and safety of new Lactobacilli mixture in patients with unconstipated irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial

O. Joo Hyun1, Y. Jang1, D. Kang2,3, D. Chang1, Y. Min1

1Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea, 2Department of Clinical Research Design and Evaluation, Samsung Medical Center, Seoul, Republic of Korea, 3Center of Clinical Epidemiology, Samsung Medical Center, Seoul, Republic of Korea.

Coffee Break

15.30 – 16.00 hrs

Symposium: Treatment of H. pylori infection

Chair: Jyhming Liou, Peter Malfertheiner

16.00 – 17.30 hrs

16.00 - 16.20

Efficacy of empirical vs. guided treatment

Liou JM, Taipei, Taiwan

 

16.20 - 16.50

Monitoring antibiotic resistance, when and how?

  • A French perspective
    Francis Mégraud, Bordeaux, France

  •  A Korean perspective
    Hwoon-Yong Jung, Seoul, Korea

16.50 - 17.10

Where are we with a vaccine?

David Graham, Houston, TX, US

 

17.10 - 17.30

Beyond antibiotics

Niyaz Ahmed, Dhaka, Bangladesh

Debate: Is Helicobacter pylori relevant in oesophageal diseases?

Chair: Günter Krejs, Colm O'Morain

17.30 – 18.00 hrs

  • Yes
    Francesco Di Mario, Parma, Italy

  • No
    Peter Malfertheiner, Munich, Germany

Closing Session

Chair: Georgina Hold, Francis Mégraud, Herbert Tilg

18.00 – 18.30 hrs

  • Awarding of the Marshall and Warren Medal to Guillermo Perez-Perez

  • EHMSG Presentation and Poster Awards

  • Presentation of the next meeting in Glasgow, United Kingdom

  • Closing remarks

EHMSG Core Agency

Vienna Medical Academy

Alser Strasse 4, 1090 Vienna, Austria

Contact

Tel.: +43 1 405 13 83 18

Fax: +43 1 405 13 83 918

© 2020

EHMSG c/o VMA

The EHMSG is a member of the United European Gastroenterology, a professional non-profit organisation combining all the leading European societies concerned with digestive disease.
UEG represents over 22,000 specialists, working across medicine, surgery, paediatrics, GI oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.

This site was designed with the
.com
website builder. Create your website today.
Start Now